Also found in: Wikipedia.


(ple-rix-a-fore) ,


(trade name)


Therapeutic: none assigned
Pharmacologic: hematopoietic stem cell mobilizers
Pregnancy Category: D


Mobilizes hematopoietic stem cells to peripheral blood for collection and use in autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma; used in combination with granulocyte-colony stimulation factor (G-CSF).


Inhibits the CXCR-4 chemokine receptor, blocking it's binding ability. Inhibition decreases adherence of stem cells to bone marrow, freeing them up to mobilize to peripheral blood.

Therapeutic effects

Mobilization of stem cells to peripheral blood allowing collection.


Absorption: Well absorbed following subcut administration.
Distribution: Largely confined to extravascular fluid space.
Metabolism and Excretion: Not metabolized by the liver; 70% unchanged in urine.
Half-life: 5.3 hr.

Time/action profile (mobilization of cells)

Subcutrapid10–14 hr*unknown
*With G-CSF pretreatment.


Contraindicated in: Hypersensitivity;Leukemia; Obstetric / Lactation: Pregnancy or lactation.
Use Cautiously in: Renal impairment (dose ↓ required if CCr ≤50 mL/min); Geriatric: Consider age-related ↓ in renal function and greater sensitivity to drug effects; Obstetric: Women with child-bearing potential; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness (most frequent)
  • fatigue (most frequent)
  • headache (most frequent)
  • insomnia


  • splenic rupture (life-threatening)
  • diarrhea (most frequent)
  • nausea (most frequent)
  • vomiting (most frequent)
  • abdominal distention/pain
  • constipation
  • dry mouth
  • dyspepsia
  • flatulence


  • erythema
  • sweating


  • leukemia/tumor cell mobilization
  • thrombocytopenia


  • injection site reactions (most frequent)


  • musculoskeletal pain


  • oral hypoesthesia


  • anaphylaxis (life-threatening)


Drug-Drug interaction

None noted.


Subcutaneous (Adults) Following pretreatment with G-CSF for 4 days—0.24 mg/kg once daily for up to 4 days (not to exceed 40 mg/day); use actual body weight to calculate dose.

Renal Impairment

Subcutaneous (Adults) Following pretreatment with G-CSF for 4 days—0.16 mg/kg once daily for up to 4 days (not to exceed 27 mg/day).


Solution for subcutaneous injection: 20 mg/mL

Nursing implications

Nursing assessment

  • Assess for splenic enlargement and potential rupture (left upper abdominal pain and/or scapular or shoulder pain) periodically during therapy.
  • Monitor for signs and symptoms of anaphylaxis (urticaria, periorbital swelling, dyspnea, hypoxia) during and for at least 30 min following administration. Discontinue therapy and treat symptomatically if symptoms occur.
  • Lab Test Considerations: Monitor WBC and platelets during therapy. May cause leukocytosis and thrombocytopenia.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Begin therapy after patient has received 4 days of G-CSF daily and approximately 11 hrs prior to initiation of apheresis.
  • Subcutaneous: Administer subcut daily for 4 days. Do not use solutions that are discolored or contain a precipitate. Vials are single use; discard any unused medication.

Patient/Family Teaching

  • Explain purpose of medication to patient.
  • Advise patient to report signs and symptoms of potential systemic reactions (urticaria, periorbital swelling, dyspnea, hypoxia) to health care professional.
  • Instruct patient to notify health care professional immediately if vasovagal reactions (orthostatic hypotension, syncope) occur during or shortly after injection.
  • Advise patient to notify health care professional if itching, rash, or reactions at injection site occur; may be treated with OTC medications.
  • May cause GI disorders including diarrhea, nausea, vomiting, flatulence, and abdominal pain. Advise patient to notify health care professional if GI disorders are severe.
  • Plerixafor is teratogenic. Caution female patients to use effective contraception during therapy and to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Increase in CD34+ cells/kg in peripheral blood prior to aphresis.
References in periodicals archive ?
sup][37] Plerixafor (also known as age-related macular degeneration (AMD)-3100, an inhibitor of CXCR4) significantly increased vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2)-positive cells in the peripheral blood, elevated SDF-1 levels, and promoted blood vessel formation in an ischemic flap model.
Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
Medication velaglucerase alfa, romiplostim, plerixafor purchase of HD and HD annex 1 below.
In addition to fresh whole blood collections, the Quincy site will soon be expanding its fresh tissue collection capabilities to include leukapheresis, a process involving enrichment of white blood cells (leukocytes), whole bone marrow aspiration, and donor mobilization using r-GCSF and/or Plerixafor to stimulate migration of hematopoietic stem cells from bone marrow into peripheral blood for leukapheresis.
In the modern method, stem cells are mobilized from the bone marrow using granulocyte colony-stimulating factor (G-CSF), often with the addition of a mobilizing agent such as Plerixafor (Mozobil), harvested from the donor's peripheral blood by apheresis, and infused to the patient after chemotherapy ablation treatment.
The Cancer Research UK Cambridge Institute researchers believe their new drug, known as AMD3100 or Plerixafor, could work even with late diagnoses.
Singapore, Nov 14, 2013 - (ACN Newswire) - Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered the exact mode of action by plerixafor, a drug commonly prescribed to stimulate immune responses in patients suffering from neutropenia, which causes them to become prone to oral, skin, genital infections and in worst cases, a fatal whole-body infection(1).
These drugs are Degarelix, Abiraterone acetate, Plerixafor, Eribulin mesylate, Mucotrol, Crizotinib, Etravirine, Nelarabine, Fingolimod, Tolvaptan, Rilpivirine, Vemurafenib, Lipiodol UF, Cabazitaxel and Panitumumab.
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
Myeloma UK said the drug, which is also known as plerixafor, is being withheld because of confusion about which NHS body in Wales should pay for it.
The North of England Cancer Drug Approvals Group has agreed a drug called Plerixafor should be made available for patients with lymphoma, cancer of the immune system, and myeloma, which affects white cells in the blood.
The North of England Cancer Drug Approvals Group has agreed a drug called Plerixafor should be made available for patients with lymphoma and myeloma who, using other treatments, have not been able to harvest stem cells which is necessary before a transplant can take place.